Table 1 Characteristics of clinical data, biochemistry and medication stratified by microvascular complications

Clinical

 Age (years)

58 ± 9

59 ± 10

ns

 Men, n (%)

67 (60)

84 (76)

0.01

 Height (cm)

174 ± 9

176 ± 9

ns

 Weight (kg)

90 ± 17

93 ± 17

ns

 BMI (kg/m²)

30 ± 5

30 ± 5

ns

 Hypertension, n (%)

64 (58)

73 (66)

ns

 Hyperlipidaemia, n (%)

77 (69)

82 (74)

ns

 Familial predisposition to IHD, n (%)

16 (14)

13 (12)

ns

 Smoking exposure (pack-years) [IQR]

2 [0–25]

9 [0–29]

ns *

 MAP (mmHg)

103 ± 10

104 ± 10

ns

 HR (beats/minute)

67 ± 13

71 ± 12

0.03

 Diabetes duration (years)

11 ± 9

16 ± 11

 < 0.001

 T2DM, n (%)

88 (79)

84 (76)

ns

Biochemistry

 Haemoglobin (mmol/L)

8.6 ± 0.7

8.5 ± 0.9

ns

 eGFR (ml/min/m²)

75 ± 9

72 ± 12

0.05

 HbA1c (mmol/mol)

59 ± 13

63 ± 15

0.02

 LDL (mmol/L)

2.0 ± 0.8

2.2 ± 0.9

ns

 HDL (mmol/L)

1.3 ± 0.5

1.3 ± 0.4

ns

 Total cholesterol (mmol/L)

4.1 ± 1.0

4.2 ± 1.1

ns

 Triglycerides (mmol/L) [IQR]

1.5 [1.1–2.4]

1.6 [1.0–2.5]

ns*

 Troponin T (ng/L) [IQR]

6 [4–9]

8 [5–12]

0.01*

 UACR (mg/g) [IQR]

9 [5–13]

24 [8–69]

 < 0.001*

Medication

 Acetylsalicylic acid, n (%)

6 (5)

16 (14)

0.03

 Clopidogrel, n (%)

2 (2)

6 (5)

ns

 Beta blockers, n (%)

12 (11)

10 (9)

ns

 Statins, n (%)

69 (62)

77 (69)

ns

 ACE inhibitor/ARB, n (%)

59 (53)

69 (62)

ns

 Calcium blockers, n (%)

19 (17)

33 (29)

0.03

 Diuretics, n (%)

31 (28)

37 (33)

ns

 Biguanides, n (%)

73 (66)

70 (63)

ns

 SGLT-2 inhibitor, n (%)

8 (7)

9 (8)

ns

 DDP-4 inhibitor, n (%)

16 (14)

16 (14)

ns

 Sulfonylureas, n (%)

13 (12)

19 (17)

ns

 GLP-1 receptor agonists, n (%)

17 (15)

22 (20)

ns

 Insulin, n (%)

52 (47)

64 (58)

ns